Research Paper Volume 16, Issue 19 pp 12769—12780
Bezafibrate mitigates cardiac injury against coronary microembolization by preventing activation of p38 MAPK/NF-κB signaling
Figure 7. Bezafibrate prevented activation of the p38 MAPK/NF-κB signaling after CME induction. (A) The levels of p-p38/p38; (B) Protein expression of nuclear NF-κB p65 (n=12, **, p<0.01 vs. control group; #, ##, p<0.05, 0.01 vs. CME group).